Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 741

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Study on the Long-Term Safety of Bepranemab for Adults with Progressive Supranuclear Palsy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bepranemab

Cardiac operation

Not recruiting

Study on Preventing Acute Kidney Injury in Cardiac Surgery Patients Using Dapagliflozin

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipatasertib

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Brain stem glioma

Not recruiting

Study on Radiotherapy with Nimotuzumab and Vinorelbine for Newly Diagnosed Childhood and Adolescent Diffuse Intrinsic Pontine Glioma (DIPG) Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nimotuzumab

Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01

Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab

Type 2 diabetes mellitus+4

Not recruiting

Study on the Effects of Alendronate on Bone and Blood Sugar Markers in Patients with Diabetes and Osteopenia/Osteoporosis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alendronate Sodium Monohydrate

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tofacitinib
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Avelumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.